Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 2nd International Conference on Tumor & Cancer Immunology and Immunotherapy Chicago, Illinois, USA .

Submit your Abstract
or e-mail to

[email protected]
[email protected]
[email protected]

Day 1 :

Tumor & Cancer immunology 2017 International Conference Keynote Speaker Weidong Han photo
Biography:

In 2001, Dr. Han obtained his Ph.D. degree in clinical hematology from Chinese PLA Postgraduate Medical School, and worked in Dept. of Molecule & Immunology of Chinese PLA General Hospital. In 2003, he did postdoctoral work at the University College London. In 2006, he was promoted to professor of molecular and cellular biology. Now, he is the director of department of molecular and cellular biology, Director of Clinical Translational Ward, the General Hospital of PLA. Since 2001, he focused on mechanism research involved in cancer-treatment resistance and clinical translation of cell therapy. He has published over 100 articles.

Abstract:

Statement of the Problem: Limited effective treatment opinions and dismal prognosis in metastatic pancreatic adenocarcinoma (mPA) and biliary tract cancers (BTCs) require developing novel therapeutic approaches. Methodology & Theoretical Orientation: Epidermal growth factor receptor (EGFR) is a well-known candidate therapeutic target due to its frequent overexpression in epithelium-derived tumors. The purpose of this study is to further expand our clinical trial (NCT01869166) of EGFR-specific chimeric antigen receptor-engineered autologous T cell (CAR T-EGFR)-based therapeutic modality to mPA and mBTCs to evaluate its feasibility and efficacy. Patients were enrolled when >50% EGFR+ ratio was observed in tumor specimens by immunohistochemical staining. CAR copy number in peripheral blood was serially measured to determine the therapeutic cycles. Findings: A total 34 of patients including 12 mPA and 22 mBTCs received 1 to 3-cycle cell infusions (Range from 0.6 to 4.1×106/kg, median dose is 2.3×106/kg) within 6 months. The acute toxicities included infusion-associated febrile syndrome (Grade 1/2 in 34 cases) and pulmonary edema/pleural effusion (Grade 3 in 4 cases). The common toxicities occurred 1 week after cell infusions included febrile syndrome (Grade 1/2 in 11 cases) accompanied with the elevation of serum cytokine such as IL6 and/or TNF, and CRP, and mucosal/cutaneous damages (Grade 1/2 in 19 cases). Of 31 patients who were treated by nab-paclitaxel/cyclophosphamide conditioned cell infusions, 5 obtained 8-16 weeks PR and 5 had 4-12 week SD in mPA patients, and 1 obtained a 22-month ongoing CR and 10 had 6-56 week SD in BTCs patients. 3 BTC patients were treated by cell infusion alone given their tolerance and relatively small disease burden, 1 obtained a 20-month ongoing CR, 1 had 8.5-month PR, and 1 had 9-month SD. Conclusion & Significance: This trial further indicated the controllable safety and efficacy of EGFR-targeted CAR T therapy, providing basis for further optimal combination strategy.

Keynote Forum

Roza Nurieva

MD Anderson Cancer Center, TX, USA

Keynote: Absence of Grail promotes CD8+ T cell anti-tumor activity

Time : 10:30-11:00

Tumor & Cancer immunology 2017 International Conference Keynote Speaker Roza Nurieva photo
Biography:

Dr. Roza Nurieva received her Ph.D. in 2000 from the Gabrichevsky Research Institute of Epidemiology and Microbiology, Moscow, Russia. Her postdoctoral fellowship, which was supported by the Arthritis Foundation, was with Dr. Chen Dong at the University of Washington, Seattle, USA, focusing on understanding the role of costimulatory molecules in regulating T helper cell activation, differentiation, and function. She is currently an Assistant Professor in the Immunology Departments at MD Anderson Cancer Center. Dr. Nurieva’s main research goal is to understand the molecular basis of T cell mediated immune responses with focus on the regulation of cytokine expression and how abnormal immune regulation leads to autoimmunity, inflammation and cancer.

Abstract:

T cell tolerance is a major obstacle to successful cancer immunotherapy; thus, it is of high priority to develop strategies to break immune tolerance. Here we report that expression of the E3 ubiquitin ligase Grail is significantly upregulated in CD8+ T cells infiltrated into transplanted lymphoma tumors and Grail-deficiency confers long-term tumor control. Importantly, therapeutic transfer of Grail-deficient CD8+ T cells was sufficient to repress established tumors. Mechanistically, loss of Grail enhanced anti-tumor reactivity and functionality of CD8+ T cells. In addition, Grail deficient CD8+ T cells exhibited increased IL-21R expression and hyper-responsiveness to IL-21 signaling as Grail promotes IL-21R ubiquitination and degradation. Moreover, CD8+ T cells isolated from lymphoma patients expressed high levels of Grail and lower levels of IL-21R compared with normal donors. Altogether, our data demonstrates that Grail is a crucial factor controlling CD8+ T cell function and is a potential target to improve CTL activity.

Keynote Forum

Gopal Krishnan

Global Product Manager- Bioassays, Promega Corporation. USA

Keynote: Quantitative and Reproducible Cell-Based Bioassays to Advance Immunotherapy Programs

Time : 11:20-11:50

Tumor & Cancer immunology 2017 International Conference Keynote Speaker Gopal Krishnan photo
Biography:

Gopal B Krishnan completed his PhD from the National Institute of Immunology, New Delhi and has worked on Early Embryonic Development and Role of Bone Morphogenetic Proteins in his Post-doctoral Fellowship at the University of Wisconsin, Madison. Before joining Promega Corp, he worked as the Team Lead for Development of DNA and siRNA transfection reagents at Mirus Bio. Currently, he is a Global Product Manager of genomics products at Promega Corp., Madison, WI. He has published over thirty peer reviewed articles, chapters and abstracts. In addition he has successfully launched fi ve new life science research products.

 

 

Abstract:

Chemotherapy and radiation therapy of cancer cells are associated with several side effects since a large population of rapidly dividing healthy cells also get destroyed. Such treatments reduce the patient’s quality of life. Therefore development of therapeutic antibodies against immune checkpoints for the treatment of cancers is gaining momentum and has already shown promising results in clinical trials. However, the functional screening and development of antibody drug candidates often relies on the use of human primary immune cells that are technically challenging to implement and highly variable. Primary peripheral blood mononuclear cells (PBMCs) are routinely used in traditional bioassays to measure potency, stability of antibody drugs. We have developed mechanism of action-based potency reporter bioassays using engineered cell lines that offer numerous advantages including optimized and rapid workflow, data reproducibility and robustness. For these reasons, and because they are easy to implement and transfer between global sites, reporter-based bioassays are now widely adopted in controlled drug development environments. 

The presentation will discuss the development of reporter based Fc bioassays and immune checkpoint reporter assays for immune checkpoint receptors utilizing engineered cell lines to serve as the effectors cells and artificial antigen presenting cells. Promega bioassays are pre-qualified to assess repeatability, intermediate precision, specificity and linearity. These bioassays are principally developed to measure the function of ADCC and ADCP mediating antibodies and immune checkpoint blocking antibodies.

  • Special Session
Location: Chicago, USA

Session Introduction

William Jia

University of British Columbia, ViroGin Biotech Ltd, Canada

Title: A novel oncolytic HSV-1 vector for cancer immunotherapy

Time : 11:50-12:50

Speaker
Biography:

William Jia has completed his PhD in 1991 at University of British Columbia (UBC) in Molecular Neurosciences. He has been an Associate Professor since 1999 at UBC and an Associate Scientist of BC Cancer Research Centre. He has been a Conjunct Professor of Fudan University, Shanghai Institute of Pharmaceutical Industry and the VP (research) for Shanghai Innovative Research Centre of Traditional Chinese Medicine (SIRC-TCM). He was the first in Canada and the first few scientists in the world using human Herpes simplex virus to treat cancer, which pioneered the field of oncolytic virotherapy for cancer treatment. He has developed one gene therapy drug for malignant gliomas has completed a phase I clinical trial in China. His most recent contribution is to raise the concept of transcription and translation dual regulated (TTDR) oncolytic viruses for cancer treatment. In the past years, he has received many awards and research funds. Since 1997, he has been a Scholar of Canadian Institute of Health Research. He has also received Petro Canada Young Inventors Award in 2007.

Abstract:

Oncolytic virotherapy has attracted increasing attention as one modality of cancer immunotherapy, especially after FDA approval of T-VEC, the first oncolytic virus (OV) drug in North America. It is now widely accepted that OV induced tumor regression is multi-mechanistic and host immune reaction plays a pivotal role. In the present study, we reported a novel oncolytic HSV-1 virus VG161 that carries three immune stimulating factors: IL12, IL15 with its receptor alpha unit and a PDL-1 blocking peptide. We have shown that this virus expresses the three major factors in infected cancer cells and shown enhanced immune cell cytotoxicity in vitro when co-cultured with PBMC. We also showed that VG161 caused stable and complete tumor regression in both syngeneic mouse tumor and human tumor in nude mouse models. The same tumor failed to grow in previously treated animals. Transcriptional profiling of the tumors treated with VG161 demonstrated a dramatically changed immune microenvironment in the tumor compared to infection with a similar virus VG160 that does not carry the anti-tumor immune stimulating factors. The above results suggest that co-expressing multiple factors by an OV can have enhanced and durable anti-tumor efficacy.  

  • Immunotherapy - Tumors Cancer Immunology & Immunotherapy Cancer Research Tumor Immunotherapy Research Tumor Markers and Drug Targetting
Location: Chicago, USA

Session Introduction

Manal Mohamed Saber

Minia University, Egypt

Title: Diagnostic and prognostic markers in Non-Hodgkin 's Lymphoma

Time : 14:45-15:10

Speaker
Biography:

Dr Manal Mohamed Saber, has earned her PhD from Nottingham, UK. she is focusing on cancer studies, EMAP II, immune suppression, molecular, cellular and laboratory techniques at a high level. She received excellent training in molecular and cellular techniques at the highest international level and has previously worked with cancer and immunology studies. Her dedication to cure cancer got her involved in cancer studies

Abstract:

Objectives:

Establishing diagnostic and prognostic factors are very important in the management of Non-Hodgkin Lymphoma (NHL). Our aim was to evaluate the clinical significance of serum cytokines and immunological markers,  in NHL patients for assessing treatment response and prognosis of patients.

Methods: Serum EMAP-II, IL-19, IL-10, IL-24, TGF-β, CD3, CD5, CD10, CD19, CD20, CD22, CD23, CD68, CD79a, CD99, LCA, bcl-2, bcl-6 and anticardiolipin (aCA) IgM, aCA IgG, antinulclear antibodies (ANA) levels were measured in the serum of 64 NHL patients before and after treatment with CHOP-based chemotherapy by enzyme-linked immunosorbent assay. Correlations of marker levels to the laboratory, and clinicopathological markers were performed.

Results: Serum levels of EMAP-II,  IL-10, CD3, CD5, CD10, CD19, CD20,  CD99 and aCA IgG were higher before therapy and decreased significantly thereafter (P<0.001). Serum CD68, CD79a and bcl-6 did not change after therapy. Significantly higher levels of IL-19, IL-24, bcl-2, CD22, CD23, LCA, TGF- β, ANA, and aCA IgM were demonstrated in patients with relapse (P<0.001). Significant associations were found between serum markers,  clinicopathological and laboratory findings.

Conclusion: Cytokines and immunological markers can serve as useful diagnostic markers in NHL patients. They assessed response to therapy. Serum IL-19, IL-24, bcl-2, CD22, CD23, LCA, TGF- β, ANA, and aCA IgM proved to be the most sensitive predictor of advanced disease and poor prognosis

Sung Hwan Lee

Yonsei University College of Medicine, Seoul, Korea

Title: Oncologic impact of postoperative delta-neutrophil index in pancreatic cancer

Time : 15:10-15:35

Speaker
Biography:

Sung Hwan Lee is currently an Clinical & Research Fellow in the Department of Surgery at Yonsei University College of Medicine, Republic of Korea. His Academic Interests are  Hepatobiliary and pancreatic surgery / Surgical oncology for pancreatic cancer / Molecular Imaging by two-photon microscopyPancreatic cancer microenvironment / Cancer metabolism

Abstract:

Background: Major cancer surgery can cause surgical stress and disturbs the immune system. The oncologic impact of perioperative immune disturbance is not yet known.

Methods: From December 2009 to December 2013, totally 154 patients who underwent pancreatic resection for pancreatic ductal adenocarcinoma were enrolled into this study. Perioperative leukocyte and lymphocyte counts assessed by an automated blood cell analyzer were obtained from institutional database. Clinicopathologic factors and survival data were identified from medical record.

Results: Immature granulocytes counted by delta neutrophil index (DNI) were significantly correlated with oncologic outcomes after curative resection of pancreatic ductal adenocarcinoma. The highest value, elevation period, and bimodality of DNI value were statistically significant predictive factors for cancer recurrence after pancreatic resection.

Conclusions: Postoperative DNI predicts the tumor recurrence after resection of pancreatic cancer. Well-designed clinical and translational researches for perioperative immune disturbance are mandatory for revealing crucial concepts for tumor immunology in veiled therapeutic viewpoint.

Speaker
Biography:

Dr. Liu is an attending surgeon of general surgery of Peking Union Medical College Hospital which successively ranks NO.1 during the last 7 years in China. He have been focusing on the integrated treatment of pancreatic cancer after curative resection, especially new treatment based on the tumor microenvironment,  for more than 10 years. He has got three national grants to support his research and also got his papers published on prestigious academic journals, including cancer research, international journal of cancer, journal of immunology and cancer immunology immunotherapy, et al.

Abstract:

Pancreatic cancer is a devastating malignance with extremely complicated tumor microenvironment. Adjuvant gemcitabine treatment is the golden standard regimen for pancreatic cancer after curative resection, however its 5-year overall survival is only 20% for this kind of patients. The correlations between tumor microenvironment and the efficacy of gemcitabine has been seldom reported. By using tumor tissue microarray technology, we analyzed the landscape of the tumor microenvironment of 95 cases of pancreatic cancer patients who underwent pancreaticoduodenectomy (Whipple procedure) and adjuvant gemcitabine treatment. The different components in the microenvironment, including the immune cell populations(Pan-inflammatory cells, B cells, Th cell , CTL, Treg, DC, NK, macrophages and granulocyte),Th1 related cytokines(IL-6, IFN-γ, TNF-α,)  ,Th2 related cytokines(IL-10, TGF-β, IL-4,IL-17), M-CSF, MG-CSF, microvascular density(MVD) and micro lymphatic vessel density(MLVD), pancreatic cancer stem cells and the immune checkpoints(PD-L1 and CTLA-4) were   immunohistologically stained. The correlations between the different patterns of tumor microenvironment and the efficacy of gemcitabine and the clinicopathological traits were analyzed. The results indicated that the tumor microenvironment was significantly correlated with the clinicopathological characteristics and the efficacy of gemcitabine.  The tumor microenvironment could be a practical indicator for personal and percisional adjuvant gemcitabine chemotherapy in pancreatic cancer patients after curative resection.

Guohui Qin

Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Title: Comparative analysis of immune molecules in esophageal squamous cell carcinoma and adenocarcinoma

Time : 16:20-16:45

Speaker
Biography:

As a PhD candidate, Ms Guohui Qin is majoring in tumor immunology, specially in tumor microenvironment. She has been studying on the role of immunosuppressive cells as myeloid-derived suppressive cells (MDSCs) and tumor initiating cells in the regulation of the proliferation and function of effective T cells in tumor microenvironment. And she has been committed to improve the efficiency of immunotherapy by blocking immunosuppressive factors. Moreover, her reports about “Blocking MDSCs accumulation in tumor site improves clinical prognosis” has been employed in Cold Spring Harbor Asia Conferences.

Abstract:

Backgrounds: Esophageal cancer has become the sixth common reason of cancer death and causes approximately 400,000 deaths worldwide annually. Esophageal cancer can be divided into esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EA) according to the histopathology. ESCC mainly distributes in Asia, correlated with smoking and drinking, while the incidence of EA which is related to gastric reflux, Barrett’s esophagus and obesity increased year by year in Western countries. Previous studies have demonstrated TP53 with a high mutation rate in both pathologies, whereas TP63/SOX2, which is associated with cell differentiation, has a high mutation rate in ESCC. However, there are few studies on the expression patterns of tumor-associated immune molecules in esophageal carcinoma. Here, we investigated the correlation between different molecules and the prognosis of different pathological esophageal cancer with the analysis of ESCC, EA and normal tissue from TCGA database. Materials and Methods: In this study, 94 different ESCC and 89 cases of EA were screened for the differentially expressed genes in tumor tissues. We investigate the distribution of increased genes in KEGG pathways. With Venn diagram Analysis we clarify the similarities and differences of gene distribution in the development of ESCC and EA. And the correlation between the screened genes and their prognosis significance was analyzed with Kaplan-Meier methods. Findings: Compared with normal tissues, the expression of 3109 genes in ESCC was increased, while 2571 genes elevated in EA. In further enrichment analysis of the elevated genes, we found that the cytokine-cytokine receptor interaction pathway may play a crucial role in the tumorigenesis and development of esophageal cancer. The Venn diagram Analysis showed that 57 genes were identical in ESCC and EA, but 18 genes were found specially increased in ESCC and other 37 related genes were only significantly elevated in EA. With survival analysis, we got that TNFRSF10B was positively and CXCL14 was negatively correlated with ESCC prognosis. And CXCL8 and IL17RB in EA were negatively correlated with survival. Our further experiments will analyze the role of TNFRSF10B, CXCL14, CXCL8 and IL17RB in ESCC and EA respectively.

Conclusion: Different molecular mechanisms play significant role in occurrence and development in ESCC and EA, which determines the different prognosis and target treatment in esophageal carcinoma.

Qiao Li

University of Michigan Comprehensive Cancer Center, USA

Title: Adoptively transferred B cells directly kill tumor cells via the CXCR4/CXCL12 and perforin pathways

Time : 16:45-17:10

Speaker
Biography:

Dr. Li is a member of the Tumor Immunology Program of the Comprehensive Cancer Center at the University of Michigan. His research to develop innovative cancer treatment approaches through adoptive immunotherapy is clinically relevant. Particularly, his recent studies focus on B cells and cancer stem cells (CSCs) represent two new directions in cancer immunotherapy.  He and his team have published a series of papers for B cells as effector cells recently. These papers respectively provided direct experimental evidence for the involvement of antibody and B cells in antitumor reactivity, demonstrating for the first time that use of in vivo sensitized and in vitro activated B cells alone could mediate tumor regression in cancer adoptive immunotherapy, and observed that effector B cells could kill target tumor cells directly in the absence of complement and other effector cells

Abstract:

Over the years, the role of B cells in the host immune response to malignancy has been overshadowed by our focus on T cells. The role played by B cells in cancer immunology is complex and controversial.  The observation made by our lab that activated B cells alone can mediate tumor regression in the adoptive immunotherapy of solid tumors is innovative. One novel mechanism by which activated B cells mediate tumor regression is via direct tumor cell cytotoxicity in the absence of antibodies.  We reported that antitumor B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10.  In this study, we defined additional mechanisms involved in B cell antitumor immunity.  Administration of IL-2 significantly augmented the therapeutic efficacy of adoptively transferred tumor-draining lymph node (TDLN) B cells which express IL-2R. Furthermore, we detected CXCR4 expression on 4T1 TDLN B cells, and 4T1 tumor cells produced its ligand CXCL12. Transwell experiments demonstrated the chemotraction of CXCR4-expressing 4T1 TDLN B cells towards CXCL12-producing 4T1 cells. Blockade of CXCR4 using a CXCR4-specific inhibitor, AMD3100, significantly reduced the killing of 4T1 tumor cells by 4T1 TDLN B cells. Blockade of FasL and CXCR4 concurrently inhibited B cell-mediated direct killing of tumor cells in an additive manner, indicating that both Fas/FasL and CXCL12/CXCR4 pathways are involved in the direct killing of 4T1 cells by 4T1 TDLN B cells. TDLN B cells produced perforin. Additional experiments showed that effector B cells could directly kill tumor cells via the Fas/FasL and CXCR4/CXCL12 pathways as well as perforin. These findings underscore the diversity of function by which B cells can play an important role in the host immune response to tumor, and clearly indicated that transferred effector B cells can act independently of T cells in causing tumor destruction in adoptive immunotherapy